

ASX Announcement
30 July 2026

Quarterly Cashflow Report & Business Update Period ending 30 June 2026

Cambium Bio Limited (ASX:CMB) (Cambium Bio or Company), a clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications, today released its quarterly cash flow report and business update for the period ending 30 June 2026 (the quarter).

Key Highlights

Item	Detail
Phase 3 IND amendment submitted	Submitted an IND amendment to the FDA on 3 June 2026 comprising the updated Phase 3 protocol, statistical analysis plan, viral clearance summary, equivalency protocol and comparability protocol. No objection or request for amendment has been received
Trial design finalised	The pivotal Phase 3 study, CAMOMILE-2, will enrol 515 patients to deliver 475 evaluable completers, on a 1:1 randomised, double-masked, vehicle-controlled design over a 9-week masked treatment period, followed by an open-label long-term safety extension
Pathogen inactivation process developed	A three-step orthogonal pathogen inactivation process for Elate Ocular® comprising low pH treatment, UV-C exposure and terminal gamma irradiation was developed during the quarter. Preliminary equivalency testing supported product equivalency
Clinical trial approvals	Ethics submissions for the updated Phase 3 protocol were progressed with Bellberry HREC in Australia and Advarra IRB in the United States, with approvals confirmed after quarter end. Vehicle control product is manufactured and available
Partnering activity	Approximately 35 meetings, the majority partnering-related, were held at the BIO International Convention in San Diego in June 2026, covering United States, European and Asian territories
Financial position	Net operating cash outflow of A\$0.799 million and closing cash of A\$1.104 million at 30 June 2026
Post quarter end funding	A placement to raise A\$1.008 million was announced on 22 July 2026. Further funding initiatives are described under Funding Strategy

FDA Regulatory Progress

Following the Type D meeting held with the FDA's Center for Biologics Evaluation and Research (CBER), Office of Therapeutic Products on 22 April 2026, at which the Agency confirmed that a single adequate and well-controlled pivotal clinical study together with confirmatory evidence is a

reasonable approach to support a Biologics License Application (BLA) for Elate Ocular®, the Company spent the quarter converting that outcome into an accepted regulatory package.

On 3 June 2026 Cambium Bio submitted an amendment to its Investigational New Drug application comprising:

- **Updated Phase 3 clinical trial protocol**, reflecting the single-trial pathway and the revised sample size.
- **Updated statistical analysis plan**, revised in accordance with the FDA's feedback at the Type D meeting.
- **Viral clearance summary**, describing the three-step orthogonal pathogen inactivation process.
- **Equivalency and comparability protocols**, covering the engineering batch and the first clinical batch.

The FDA acknowledged receipt of the submission and confirmed that it had no questions at that time. As at the date of this announcement the Company has received no objection to, or request to amend, the updated protocol or statistical analysis plan, and is proceeding on that basis.

All previously secured regulatory foundations remain in place, including FDA Fast Track Designation (granted 4 December 2024), FDA Orphan Drug Designation for dry eye disease secondary to chronic graft-versus-host disease, the FDA-approved potency assurance strategy (March 2025), and ethics committee approvals in Australia (Bellberry HREC) and the United States (Advarra IRB). Consistent with the FDA's advice at the Type D meeting, the nature and scope of confirmatory evidence will be discussed with the Agency following Phase 3 topline readout.

Pivotal Phase 3 Trial Design

The design of the single pivotal Phase 3 study was finalised during the quarter and is summarised below. The study previously designated CAMOMILE-3 has been redesignated CAMOMILE-2.

The FDA confirmed at the Type D meeting on 22 April 2026 that the previously agreed study design, at 400 evaluable subjects, remained acceptable to support the single-trial BLA pathway. The increase to 475 evaluable completers is a Company-initiated change arising from the revised statistical analysis plan, and was submitted to the FDA as part of the 3 June 2026 IND amendment.

Parameter	Detail
Study	CAMOMILE-2, pivotal Phase 3, moderate to severe dry eye disease
Design	Randomised 1:1, double-masked, vehicle-controlled, multicentre
Enrolment	515 patients enrolled to deliver 475 evaluable completers
Treatment period	9-week masked treatment period, followed by an open-label long-term safety extension
Co-primary endpoints	Corneal Fluorescein Staining Index (sign) and VAS Eye Discomfort Score (symptom), assessed at Week 9
Geographies	Australia and the United States
Registration	NCT06903611 (United States); CT-2025-CTN-02208-1-v2 (Australia)

The randomised treatment phase and the open-label extension will be maintained in separate clinical databases, consistent with the data firewall arrangements requested by the FDA. This permits the randomised database to be locked at last patient last visit without waiting for completion of the extension.

CMC and Manufacturing Progress

Cambium Bio continued to advance the Chemistry, Manufacturing and Controls (CMC) programme for Elate Ocular® during the quarter, with the objective of releasing Phase 3 clinical supply:

- **Pathogen inactivation:** A three-step orthogonal pathogen inactivation process comprising low pH treatment of the bulk drug substance, UV-C exposure of the drug product, and terminal gamma irradiation was developed. This replaces the single inactivation step previously incorporated in the manufacturing process and is intended to strengthen the viral safety profile of the product. Acceptance of the viral clearance package remains subject to FDA review.
- **Equivalency testing:** Preliminary equivalency testing completed during the quarter supported equivalency for the low pH and UV-C steps.
- **Process equipment:** A UV-C flow-through device was specified and built during the quarter, and delivered for viral clearance testing shortly after quarter end.
- **Analytical and stability programme:** Release testing methods were progressed, including particulate matter, endotoxin and potency testing, and the stability protocol for the Phase 3 investigational product was defined.
- **Manufacturing readiness:** The Company's contract development and manufacturing organisation reserved cleanroom capacity for the engineering batch. Raw material for the engineering batch and first clinical batch was sourced during the quarter and ordered after quarter end.

The engineering batch is intended to incorporate all three pathogen inactivation steps and to be subject to full in-process control and release testing. Manufacture of the engineering batch and the first clinical batch is targeted for the second half of CY 2026, subject to confirmation of batch scope and manufacturing capacity with the Company's contract development and manufacturing organisation. The combined three-step process has not yet been manufactured at full scale, and manufacturing outcomes remain subject to normal biological process risk.

Clinical Operations Readiness

- **Ethics and regulatory approvals:** Ethics submissions for the updated Phase 3 protocol were progressed with Bellberry HREC in Australia and Advarra IRB in the United States during the quarter, with approvals confirmed after quarter end. The Australian Clinical Trial Notification remains current.
- **Vehicle control supply:** Vehicle control product for the study has been manufactured and is available.
- **Contract research organisation:** Selection of the contract research organisation for the pivotal study was concluded and contracting was advanced during and after the quarter. Execution of the master services agreement and payment of the associated deposit are the principal gating steps to site activation and First Patient In. The deposit is material relative to the Company's cash balance at 30 June 2026, and its payment is contingent on the funding initiatives described under Funding Strategy.
- **Site selection:** Initial clinical sites in Australia and the United States were identified, which have existing agreements in place with the selected contract research organisation. The Company expects this to support timely activation.

Business Development

The Company attended the BIO International Convention in San Diego in June 2026, holding approximately 35 meetings, the majority of which related to partnering. Counterparties expressed interest in United States rights and, separately, in European and Asian territories. The Company also held partnering and investor meetings at BIO Asia Taiwan in July 2026, after quarter end.

Cambium Bio intends to consider a structured out-licensing process following commencement of the pivotal Phase 3 trial, when the timing of topline data can be established with greater confidence. No

terms have been agreed with any counterparty and there is no assurance that any transaction will result.

Development Timeline

Reflecting regulatory, CMC and clinical operations progress during the quarter, the Company provides the following indicative development timeline for Elate Ocular®:

Milestone	Indicative Timing
First Patient In (CAMOMILE-2 pivotal Phase 3)*	Q4 CY 2026
Topline data read-out	Q4 CY 2027
Rolling BLA submission (under Fast Track Designation)	Mid-CY 2028
Potential BLA approval	Late CY 2028 / early CY 2029

** First Patient In is contingent on the Company securing additional equity funding and on execution of contract research organisation agreements. Forward-looking timelines are subject to risks and uncertainties, including further FDA interactions, manufacturing readiness, site activation pace, patient enrolment and financing conditions. Refer to the Forward-Looking Statements disclaimer at the end of this announcement.*

Financial Summary (Appendix 4C)

Cambium Bio's June quarter cash movements reflect continued investment in Phase 3 readiness for Elate Ocular® alongside tight cost discipline:

Net operating cash outflow: A\$0.799 million

- Receipts from customers of A\$0.150 million comprised recurring royalty income from the Company's fibrinogen-depleted human platelet lysate (FD hPL) cell culture supplement products.
- Research and development expenditure of A\$0.654 million, representing approximately 69% of total operating payments, was directed to pathogen inactivation and viral clearance work, analytical and stability activities, regulatory submissions, and clinical trial preparation.
- Staff costs of A\$0.162 million reflect the Company's lean operating model, which leverages contract development, manufacturing and research partners rather than a permanent in-house workforce.
- Administration and corporate costs were contained at A\$0.129 million.
- Interest and other costs of finance paid of A\$0.004 million relate to the unsecured senior note described under Additional Disclosures.

Investing cash flows: nil

- There were no investing cash flows during the quarter.

Net financing cash outflow: A\$0.261 million

- Comprising repayment of the tranche of the unsecured senior note that matured in April 2026.

Closing cash balance: A\$1.104 million (30 June 2026)

- The movement from A\$2.246 million at 31 March 2026 reflects the operating and financing outflows above and an unfavourable foreign exchange movement of A\$0.082 million on cash held.

Funding available

- Item 8.5 of the Appendix 4C reports estimated quarters of funding available of less than two quarters, on the basis of cash at 30 June 2026 and the net operating cash outflow for the quarter. The Company expects operating cash outflows to increase as the pivotal Phase 3 trial

commences. Responses to items 8.6.1, 8.6.2 and 8.6.3 of the Appendix 4C set out the steps the Company is taking to raise further cash and the basis on which it expects to continue its operations.

For the twelve months to 30 June 2026, net operating cash outflow was A\$2.830 million, proceeds from the issue of equity securities were A\$4.574 million, and government grants and tax incentives received were A\$0.584 million.

Additional Disclosures

- **Related-party payments:** A\$0.256 million for the quarter, comprising directors' fees and CEO remuneration, in accordance with statutory disclosure requirements (refer to item 6 of the Appendix 4C).
- **Loan facilities:** The tranche of the unsecured senior note that matured on 7 April 2026 was repaid in full, with accrued interest, during the quarter. The remaining tranche of US\$98,000, A\$0.158 million equivalent at quarter end, is unsecured, bears interest at 5% per annum and matures on 7 August 2026 (refer to item 7 of the Appendix 4C).

Management continues to monitor expenditure closely and retains the flexibility to phase research and development commitments, including the timing and pace of the pivotal Phase 3 trial, in line with funding available to the Company.

Funding Strategy

The Board is pursuing a multi-pronged funding strategy to support the pivotal Phase 3 programme through to topline data and BLA submission:

- **Placement completed after quarter end:** On 22 July 2026 the Company announced a firm commitment to raise A\$1,008,000 through the issue of 2,100,000 fully paid ordinary shares at A\$0.48 per share, under its existing 10% placement capacity under Listing Rule 7.1A as approved by shareholders at the Annual General Meeting held on 16 October 2025. Settlement and issue of the shares occurred in July 2026, after the end of the quarter.
- **Research and development tax incentive:** The Company expects to receive a research and development tax incentive (RDTI) rebate for FY2026 of approximately A\$1.0 million in October or November 2026.
- **RDTI pre-financing:** The Company is finalising financing documentation to pre-finance its FY2027 RDTI rebate for an amount of A\$3.75 million. Documentation has not been executed and no binding agreement has been entered into as at the date of this announcement.
- **Additional equity:** The Company is undertaking additional equity capital raising activities to fund the upcoming pivotal Phase 3 trial.
- **Licensing transactions:** Discussions for Elate Ocular® licensing rights in regional markets are ongoing and may provide a source of non-dilutive capital.
- **Royalty income:** Continued recurring royalties from the Company's FD hPL cell culture supplement products.

Commencement of the pivotal Phase 3 trial, including execution of contract research organisation contracting and payment of the associated deposit, is contingent on the Company securing additional funding. The funding initiatives that are not yet complete remain subject to execution of documentation, market conditions and investor demand, and there is no assurance that they will be completed on acceptable terms or at all.

CEO Commentary

Karolis Rosickas, Chief Executive Officer of Cambium Bio, commented:

"The June quarter was about converting the FDA's confirmation of the single pivotal trial pathway into an accepted, executable plan. We submitted the updated protocol, statistical analysis plan and the full pathogen inactivation package to the FDA on 3 June, and we have received no objection. We developed a three-step orthogonal pathogen inactivation process, and preliminary

equivalency testing supported the two new steps. The trial is approved by ethics committees in both Australia and the United States, the vehicle control is manufactured, and our sites and contract research organisation are identified and ready to activate. What remains is capital. We completed a placement in July, we expect our FY2026 RDTI rebate in October or November, we are finalising documentation to pre-finance the FY2027 rebate, and we are pursuing additional equity. Our objective is First Patient In in the fourth quarter of this calendar year, and that objective is funding-dependent.”

Subsequent Events

The following events have occurred after the reporting period and prior to the release of this announcement:

1. Placement of A\$1,008,000 (22 July 2026)

On 22 July 2026 the Company announced a firm commitment to raise A\$1,008,000 through the issue of 2,100,000 fully paid ordinary shares at A\$0.48 per share, representing a **17.1% premium** to the closing share price of A\$0.41 on 21 July 2026. The shares were issued under the Company’s existing 10% placement capacity under Listing Rule 7.1A and no shareholder approval was required. The placement was subscribed by an existing shareholder who is not a related party of the Company, and whose relevant interest increases from approximately 12.25% to approximately 18.5%. Settlement and issue occurred in July 2026.

2. FDA review of the IND amendment

More than 30 days have elapsed since submission of the IND amendment on 3 June 2026. The Company has received no objection to, or request to amend, the updated protocol or statistical analysis plan, and is proceeding on that basis.

3. Manufacturing readiness

Viral clearance testing of the UV-C flow-through device was carried out in July 2026, with results being finalised by the testing laboratory. The device has been despatched to the Company’s contract development and manufacturing organisation, and raw material for the engineering batch has been ordered. Ethics approval of the updated Phase 3 protocol was confirmed by Bellberry HREC in Australia and Advarra IRB in the United States.

4. Senior note maturity

The remaining tranche of the unsecured senior note, A\$0.158 million equivalent at quarter end, matures on 7 August 2026.

Outlook – Key Milestones (next 18 months)

Milestone	Indicative Timing
Execution of contract research organisation agreements	Q3 CY 2026
Manufacture of Phase 3 engineering batch and first clinical batch	H2 CY 2026
Site activation in Australia and the United States	Q4 CY 2026
First Patient In (CAMOMILE-2 pivotal Phase 3)*	Q4 CY 2026
Receipt of FY2026 RDTI rebate	October / November 2026
Complete Phase 3 enrolment	H1 CY 2027
Topline data read-out	Q4 CY 2027

* Subject to additional funding, as described under Funding Strategy.

– ENDS –

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialisation, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio.

Forward-Looking Statements

This announcement contains forward-looking statements regarding Cambium Bio's clinical development plans, regulatory pathway, manufacturing activities, financing initiatives, the expected timing, scope and outcome of the pivotal Phase 3 clinical study for Elate Ocular®, and the timing of any potential BLA submission and approval. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. These factors include, but are not limited to, the availability and timing of further financing, regulatory delays, clinical trial outcomes, the requirement for additional clinical or nonclinical evidence, manufacturing scale-up and supply chain challenges, site activation and patient enrolment rates, the amount and timing of research and development tax incentive rebates, the success of licensing and partnership discussions, and general market conditions. Regulatory and clinical outcomes are not certain, and target dates are qualified targets and not commitments. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this announcement. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

For further information, please contact:

Acclime Australia – Company Secretary
Email: info@cambium.bio

Cambium Bio Limited

Unit 2.06/31 Lexington Drive, Bella Vista, NSW 2153 Australia

ABN 13 127 035 358

Phone: 1300 995 098

www.cambium.bio

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Cambium Bio Limited

ABN

13 127 035 358

Quarter ended ("current quarter")
30th June 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	150	666
1.2 Payments for		
(a) research and development	(654)	(2,567)
(b) product manufacturing and operating costs	0	0
(c) advertising and marketing	0	0
(d) leased assets	0	0
(e) staff costs	(162)	(922)
(f) administration and corporate costs	(129)	(550)
1.3 Dividends received (see note 3)	0	0
1.4 Interest received	0	0
1.5 Interest and other costs of finance paid	(4)	(41)
1.6 Income taxes paid	0	0
1.7 Government grants and tax incentives	0	584
1.8 Other (provide details if material)	0	0
1.9 Net cash from / (used in) operating activities	(799)	(2,830)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	0	0
(b) businesses	0	0
(c) property, plant and equipment	0	(3)
(d) investments	0	0
(e) intellectual property	0	0
(f) other non-current assets	0	0

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	0	0
	(b) businesses	0	0
	(c) property, plant and equipment	0	0
	(d) investments	0	0
	(e) intellectual property	0	0
	(f) other non-current assets	0	0
2.3	Cash flows from loans to other entities	0	0
2.4	Dividends received (see note 3)	0	0
2.5	Other (merger expenses)	0	(320)
2.6	Net cash from / (used in) investing activities	0	(323)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	0	4,574
3.2	Proceeds from issue of convertible debt securities	0	0
3.3	Proceeds from exercise of options	0	0
3.4	Transaction costs related to issues of equity securities or convertible debt securities	0	0
3.5	Proceeds from borrowings	0	0
3.6	Repayment of borrowings	(261)	(320)
3.7	Transaction costs related to loans and borrowings	0	0
3.8	Dividends paid	0	0
3.9	Other (provide details if material)	0	0
3.10	Net cash from / (used in) financing activities	(261)	4,254

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	2,246	166
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(799)	(2,830)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(0)	(323)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(261)	4,254
4.5	Effect of movement in exchange rates on cash held	(82)	(163)
4.6	Cash and cash equivalents at end of period	1,104	1,104

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,104	2,246
5.2	Call deposits	0	0
5.3	Bank overdrafts	0	0
5.4	Other (provide details)	0	0
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,104	2,246

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	256
6.2	Aggregate amount of payments to related parties and their associates included in item 2	0
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	158	158
7.2 Credit standby arrangements	0	0
7.3 Other (please specify)	0	0
7.4 Total financing facilities	158	158
7.5 Unused financing facilities available at quarter end		0
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well. Cambium Medical Technologies, LLC (CMT) entered into a Senior Note Purchase Agreement with Georgia Research Alliance, LLC in April 2017. It is an unsecured loan of US\$250,000 at a 5% interest rate per annum. The US\$152,000 tranche matured on 7 April 2026 and was repaid in full, with accrued interest, during the quarter (refer to item 3.6). The remaining tranche of US\$98,000 with accrued interest, A\$158,000 equivalent at quarter end, matures on 7 August 2026. The facility is fully drawn and no undrawn amount is available at quarter end (refer to item 7.5). Proposed facility after quarter end: the Company is finalising financing documentation in relation to a facility to pre-finance its FY2027 research and development tax incentive rebate for an amount of A\$3.75 million. That documentation has not been executed and no binding agreement has been entered into as at the date of this report. Terms, including interest rate, maturity and security, will be confirmed on execution.		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(799)
8.2 Cash and cash equivalents at quarter end (item 4.6)	1,104
8.3 Unused finance facilities available at quarter end (item 7.5)	0
8.4 Total available funding (item 8.2 + item 8.3)	1,104
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	(1.38)
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: No. The Company expects net operating cash outflows to increase in future quarters as the pivotal Phase 3 clinical trial commences, including contract research organisation fees, site activation costs and manufacture of the Phase 3 investigational drug product. The timing and scale of that increase is dependent on the funding initiatives described in item 8.6.2.	

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: Yes.

- On 22 July 2026 the Company announced a placement to raise A\$1,008,000 through the issue of 2,100,000 fully paid ordinary shares at A\$0.48 per share under its existing capacity under Listing Rule 7.1A. The placement was completed in July 2026, after the end of the quarter.
- The Company expects to receive a research and development tax incentive (RDTI) rebate for FY2026 of approximately A\$1.0 million in October or November 2026.
- The Company is in advanced final documentation discussions to pre-finance its FY2027 RDTI rebate for an amount of A\$3.75 million. Documentation has not been executed and no binding agreement has been entered into as at the date of this report.
- The Company is undertaking additional equity capital raising activities to fund the upcoming pivotal Phase 3 trial of Elate Ocular®.

The Company believes these steps are reasonably likely to be successful, having regard to the completion of the July 2026 placement, its history of RDTI receipts and equity raisings, and the advanced stage of the RDTI pre-financing documentation. The initiatives that are not yet complete remain subject to execution of documentation, market conditions and investor demand, and there is no assurance that they will be completed on acceptable terms or at all.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: Yes. The Company expects to continue its operations and to meet its business objectives on the basis of:

- cash and cash equivalents of A\$1.104 million at 30 June 2026;
- proceeds of A\$1,008,000 from the placement completed in July 2026, after the end of the quarter;
- the expected FY2026 RDTI rebate of approximately A\$1.0 million, anticipated in October or November 2026;
- the proposed pre-financing of the FY2027 RDTI rebate for A\$3.75 million, currently in advanced final documentation; and
- additional equity capital raising activities being undertaken to fund the pivotal Phase 3 trial of Elate Ocular®.

The Company also retains the ability to manage the timing and scale of its research and development expenditure, including the commencement and pace of the pivotal Phase 3 trial, to align with funding available to it. The statements above are forward-looking and are subject to risks and uncertainties, including the completion of the RDTI pre-financing documentation, the amount and timing of the RDTI rebate, and the outcome of the Company's capital raising activities.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 July 2026

Authorised by: The Board of Cambium Bio Limited
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.